News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
GlaxoSmithKline Partner Pronova BioPharma Settles Drug Case with Apotex Inc.; Apotex to Sell Generic Lovaza in U.S. from Q1 2015
March 30, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, March 30 (Reuters) - Norway's Pronova BioPharma (PRON.OL), which supplies the omega-3 heart medicine Lovaza to GlaxoSmithKline (GSK.L), settled a U.S. patent row with generics company Apotex, sending Pronova shares sharply higher.
Twitter
LinkedIn
Facebook
Email
Print
Legal
GlaxoSmithKline
MORE ON THIS TOPIC
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
·
1 min read
·
Lori Ellis
Government
Hundreds of HHS Staffers Accuse RFK Jr. of ‘Sowing Public Mistrust’ Against CDC After Shooting at HQ
August 21, 2025
·
2 min read
·
Tristan Manalac
Vaccines
American Academy of Pediatrics Contradicts CDC, Recommends COVID-19 Shot for Kids
August 20, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Conflicts of Interest in Vaccine Committees Have Been Plunging for Decades
August 19, 2025
·
4 min read
·
Dan Samorodnitsky